Biogen (BIIB), it’s your turn.

I’m speaking of an acquisition, of course. The $9 billion purchase of Juno Therapeutics by Celgene announced Monday, which followed Gilead Sciences’s nearly $12 billion acquisition of Kite Pharma last year, shifts the M&A spotlight to Cambridge-based Biogen.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.